AcelRx Pharmaceuticals (NASDAQ:ACRX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Get Rating) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Several other brokerages have also recently issued reports on ACRX. HC Wainwright cut AcelRx Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, March 14th. Zacks Investment Research cut AcelRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, March 15th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of AcelRx Pharmaceuticals in a research note on Friday, March 11th.

AcelRx Pharmaceuticals stock opened at $0.24 on Wednesday. The stock has a 50-day moving average of $0.33 and a two-hundred day moving average of $0.53. AcelRx Pharmaceuticals has a one year low of $0.22 and a one year high of $1.67. The stock has a market cap of $35.99 million, a PE ratio of -0.84 and a beta of 0.67.

AcelRx Pharmaceuticals (NASDAQ:ACRX – Get Rating) last released its quarterly earnings results on Thursday, March 10th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of ($0.06). During the same period in the previous year, the firm earned ($0.10) earnings per share. Equities research analysts predict that AcelRx Pharmaceuticals will post -0.22 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the stock. Rock Springs Capital Management LP grew its holdings in AcelRx Pharmaceuticals by 0.8% during the third quarter. Rock Springs Capital Management LP now owns 3,819,402 shares of the specialty pharmaceutical company’s stock worth $3,896,000 after acquiring an additional 30,645 shares during the period. D. E. Shaw & Co. Inc. grew its holdings in AcelRx Pharmaceuticals by 12.3% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 3,721,586 shares of the specialty pharmaceutical company’s stock worth $2,085,000 after acquiring an additional 407,507 shares during the period. Values First Advisors Inc. acquired a new stake in AcelRx Pharmaceuticals during the fourth quarter worth about $291,000. Millennium Management LLC grew its holdings in AcelRx Pharmaceuticals by 40.1% during the fourth quarter. Millennium Management LLC now owns 334,248 shares of the specialty pharmaceutical company’s stock worth $187,000 after acquiring an additional 95,716 shares during the period. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in AcelRx Pharmaceuticals during the third quarter worth about $143,000. 15.93% of the stock is currently owned by hedge funds and other institutional investors.

About AcelRx Pharmaceuticals (Get Rating)

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures.

Featured Stories